<DOC>
	<DOCNO>NCT00732615</DOCNO>
	<brief_summary>Use PTH ( 1-84 ) recombinant hormone escalating dose treatment adult hypoparathyroidism . The use PTH result decrease calcium vitamin D supplement .</brief_summary>
	<brief_title>Use NPSP558 Treatment Hypoparathyroidism</brief_title>
	<detailed_description>Patients history hypoparathyroidism randomize receive placebo study drug 24 week , inject daily either thigh . During time monitor safety ( specifically , calcium level blood urine ) . In addition , patient ' intake Vitamin D calcium measure .</detailed_description>
	<mesh_term>Hypoparathyroidism</mesh_term>
	<criteria>Inclusion Criteria Patients meet follow inclusion criterion enrol potentially randomize study : Adult male females 18 85 year age ( prior screening ) History hypoparathyroidism ≥ 18 month Requirement vitamin D metabolite/analog therapy calcitriol ≥0.25 μg per day alphacalcidol ≥0.50 μg per day prior randomization . Requirement supplemental oral calcium treatment ≥ 1000 mg per day normal dietary calcium intake Serum thyroid function test within normal laboratory limit screen Serum magnesium level within laboratory normal limit Serum 25hydroxyvitamin D [ 25 ( OH ) D ] level ≤ 1.5fold laboratory upper limit normal Creatinine clearance &gt; 30 mL/min two separate measurement OR creatinine clearance &gt; 60 mL/min AND serum creatinine &lt; 1.5 mg/dL With regard female patient : woman postmenopausal woman surgically sterilize enrol . Women childbearing potential must negative pregnancy test Randomization willing use two medically acceptable method contraception duration study . Exclusion Criteria Patients follow screen visit eligible enrollment study : Known history hypoparathyroidism result activate mutation CaSR gene impair responsiveness PTH ( pseudohypoparathyroidism ) Any disease might affect calcium metabolism calciumphosphate homeostasis hypoparathyroidism , active hyperthyroidism , Paget 's disease , insulin dependent diabetes mellitus ( IDDM ) poorly control Type II diabetes mellitus ( HbA1C &gt; 8 % ) , severe chronic cardiac , liver renal disease , Cushing 's syndrome , neuromuscular disease rheumatoid arthritis , myeloma , pancreatitis , malnutrition , rickets , recent prolonged immobility , active malignancy , primary secondary hyperparathyroidism , history parathyroid carcinoma , hypopituitarism , acromegaly , multiple endocrine neoplasia type I II Patients history thyroid cancer must document diseasefree period least 5 year Patients dependent regular parenteral calcium infusion ( eg calcium gluconate ) maintain calcium homeostasis Patients undergone gastric resection active peptic ulcer disease require medical therapy Use prohibit medication loop thiazide diuretic , raloxifene hydrochloride , lithium , estrogens progestin hormone replacement therapy , methotrexate , systemic corticosteroid within respective prohibit period Previous treatment PTHlike drug , include PTH ( 184 ) , PTH ( 134 ) Nterminal fragment analogs PTH PTHrelated protein within 6 month prior screen Other drug know influence calcium bone metabolism , calcitonin , fluoride tablet , cinacalcet hydrochloride within prohibited period Use oral bisphosphonates within previous 6 month IV bisphosphonate preparation within previous 12 month prior screen Seizure disorder/epilepsy history seizure within previous 6 month prior screen Presence open epiphysis Irradiation ( radiotherapy ) skeleton within 5 year Serum 25hydroxyvitamin D level great 1.5fold laboratory upper limit normal Participation investigational trial receipt investigational drug device occur within 6 month prior screen study Pregnant lactate woman History diagnose drug alcohol dependence within previous 3 year Clinical history renal calculus within past 12 month History gout Disease process may adversely affect gastrointestinal absorption , include limited short bowel syndrome , bowel resection , tropical sprue , celiac disease , ulcerative colitis , Crohn 's disease Chronic/severe cardiac disease include limited cardiac insufficiency , arrhythmia , bradycardia ( rest heart rate &lt; 60 beats/minute ) , hypotension ( systolic diastolic blood pressure &lt; 100 60 mmHg , respectively ) History cerebrovascular accident ( CVA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Hypoparathyroidism</keyword>
</DOC>